We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ltd - Hong Kong-based biopharmaceutical firm - Is to receive a USD10 million milestone payment from partner Takeda Pha ...
Hutchmed (China) Limited 13 December 2024 Press Release HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib) - US$10...
Hutchmed (China) Limited 12 December 2024 Press Release HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients...
Hutchmed China Ltd on Tuesday reported it was granted conditional approval in China for an injection to treat endomet ...
Hutchmed (China) Limited 03 December 2024 Press Release HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab...
Hutchmed (China) Limited 29 November 2024 Total Voting Rights Hong Kong, Shanghai & Florham Park, NJ - Friday, November 29, 2024: HUTCHMED (China) Limited ("HUTCHMED...
Hutchmed (China) Limited 28 November 2024 Press Release HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms...
Hutchmed (China) Ltd on Friday said it will receive a milestone payment from Takeda Pharmaceutical Co Ltd after Taked ...
Hutchmed (China) Limited 22 November 2024 Press Release HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan - Launch follows approval by Japanese Ministry of...
Hutchmed (China) Limited 20 November 2024 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee Hong Kong, Shanghai & Florham Park, NJ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -12 | -4.81927710843 | 249 | 260 | 228 | 77341 | 241.25613966 | DE |
4 | -42 | -15.0537634409 | 279 | 300 | 228 | 59964 | 263.79573504 | DE |
12 | -43 | -15.3571428571 | 280 | 336 | 228 | 131693 | 297.92744699 | DE |
26 | -43 | -15.3571428571 | 280 | 336 | 228 | 102146 | 291.65182782 | DE |
52 | -41 | -14.7482014388 | 278 | 353 | 190.4 | 84735 | 285.01063722 | DE |
156 | -293 | -55.2830188679 | 530 | 540 | 130 | 98258 | 257.20172184 | DE |
260 | -139 | -36.9680851064 | 376 | 656 | 130 | 100750 | 349.5445725 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions